Does the media refer more to MBX or COLL?

In the previous week, Collegium Pharmaceutical had 5 more articles in the media than MBX Biosciences. MarketBeat recorded 6 mentions for Collegium Pharmaceutical and 1 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.16 beat Collegium Pharmaceutical's score of 0.03 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LQDA or COLL?

In the previous week, Liquidia had 34 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 40 mentions for Liquidia and 6 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.03 beat Liquidia's score of -0.13 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 4 Very Positive mention(s) 8 Positive mention(s) 12 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Collegium Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, COLL or HCM?

HUTCHMED has lower revenue, but higher earnings than Collegium Pharmaceutical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Collegium Pharmaceutical $780.57M 0.92 $62.87M $1.24 17.83 HUTCHMED $549.12M 4.34 $456.91M N/A N/A

Does the media prefer COLL or HCM?

In the previous week, Collegium Pharmaceutical had 4 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for Collegium Pharmaceutical and 2 mentions for HUTCHMED. Collegium Pharmaceutical's average media sentiment score of 0.03 beat HUTCHMED's score of -0.20 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral HUTCHMED 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Collegium Pharmaceutical (COLL) Competitors

$22.09 -0.02 (-0.09%)

Closing price 04:00 PM Eastern

Extended Trading

$22.06 -0.03 (-0.14%)

As of 06:43 PM Eastern

Compare

COLL vs. MOR, MBX, LQDA, HCM, and SUPN

Should you buy Collegium Pharmaceutical stock or one of its competitors? Collegium Pharmaceutical's main competitors and comparable companies include MorphoSys (MOR), MBX Biosciences (MBX), Liquidia (LQDA), HUTCHMED (HCM), and Supernus Pharmaceuticals (SUPN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Collegium Pharmaceutical compare to MorphoSys?

Collegium Pharmaceutical (NASDAQ:COLL) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Collegium Pharmaceutical has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Collegium Pharmaceutical has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	0.92	$62.87M	$1.24	17.83
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

In the previous week, Collegium Pharmaceutical had 6 more articles in the media than MorphoSys. MarketBeat recorded 6 mentions for Collegium Pharmaceutical and 0 mentions for MorphoSys. Collegium Pharmaceutical's average media sentiment score of 0.03 beat MorphoSys' score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Overall Sentiment
Collegium Pharmaceutical	Neutral
MorphoSys	Neutral

18.4% of MorphoSys shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Collegium Pharmaceutical has a net margin of 5.93% compared to MorphoSys' net margin of -226.79%. Collegium Pharmaceutical's return on equity of 91.43% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
MorphoSys	-226.79%	-694.31%	-22.55%

Collegium Pharmaceutical presently has a consensus target price of $48.71, indicating a potential upside of 120.33%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, equities research analysts clearly believe Collegium Pharmaceutical is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Collegium Pharmaceutical beats MorphoSys on 13 of the 16 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Collegium Pharmaceutical (NASDAQ:COLL) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Collegium Pharmaceutical has a net margin of 5.93% compared to MBX Biosciences' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 91.43% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

MBX Biosciences currently has a consensus target price of $83.89, suggesting a potential upside of 57.54%. Collegium Pharmaceutical has a consensus target price of $48.71, suggesting a potential upside of 120.33%. Given Collegium Pharmaceutical's higher possible upside, analysts clearly believe Collegium Pharmaceutical is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Collegium Pharmaceutical	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

Collegium Pharmaceutical has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Collegium Pharmaceutical	$780.57M	0.92	$62.87M	$1.24	17.83

In the previous week, Collegium Pharmaceutical had 5 more articles in the media than MBX Biosciences. MarketBeat recorded 6 mentions for Collegium Pharmaceutical and 1 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.16 beat Collegium Pharmaceutical's score of 0.03 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Collegium Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

MBX Biosciences has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

Summary

Collegium Pharmaceutical beats MBX Biosciences on 10 of the 14 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Collegium Pharmaceutical (NASDAQ:COLL) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Liquidia has a net margin of 30.74% compared to Collegium Pharmaceutical's net margin of 5.93%. Liquidia's return on equity of 149.65% beat Collegium Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

Liquidia has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

In the previous week, Liquidia had 34 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 40 mentions for Liquidia and 6 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.03 beat Liquidia's score of -0.13 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	4 Very Positive mention(s)	8 Positive mention(s)	12 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral
Collegium Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Collegium Pharmaceutical has higher revenue and earnings than Liquidia. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	15.84	-$68.92M	$1.37	20.45
Collegium Pharmaceutical	$780.57M	0.92	$62.87M	$1.24	17.83

Liquidia presently has a consensus price target of $83.69, suggesting a potential upside of 198.69%. Collegium Pharmaceutical has a consensus price target of $48.71, suggesting a potential upside of 120.33%. Given Liquidia's higher possible upside, equities research analysts plainly believe Liquidia is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25
Collegium Pharmaceutical	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

64.5% of Liquidia shares are held by institutional investors. 25.6% of Liquidia shares are held by company insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Liquidia beats Collegium Pharmaceutical on 11 of the 17 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to HUTCHMED?

Collegium Pharmaceutical (NASDAQ:COLL) and HUTCHMED (NASDAQ:HCM) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

8.8% of HUTCHMED shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 3.6% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

HUTCHMED has lower revenue, but higher earnings than Collegium Pharmaceutical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	0.92	$62.87M	$1.24	17.83
HUTCHMED	$549.12M	4.34	$456.91M	N/A	N/A

In the previous week, Collegium Pharmaceutical had 4 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for Collegium Pharmaceutical and 2 mentions for HUTCHMED. Collegium Pharmaceutical's average media sentiment score of 0.03 beat HUTCHMED's score of -0.20 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
HUTCHMED	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Collegium Pharmaceutical has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market.

Collegium Pharmaceutical currently has a consensus target price of $48.71, indicating a potential upside of 120.33%. HUTCHMED has a consensus target price of $14.87, indicating a potential upside of 8.75%. Given Collegium Pharmaceutical's higher possible upside, analysts plainly believe Collegium Pharmaceutical is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
HUTCHMED	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Collegium Pharmaceutical has a net margin of 5.93% compared to HUTCHMED's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 91.43% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
HUTCHMED	N/A	N/A	N/A

Summary

Collegium Pharmaceutical beats HUTCHMED on 9 of the 15 factors compared between the two stocks.

How does Collegium Pharmaceutical compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Collegium Pharmaceutical (NASDAQ:COLL) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Supernus Pharmaceuticals currently has a consensus target price of $62.83, suggesting a potential upside of 49.11%. Collegium Pharmaceutical has a consensus target price of $48.71, suggesting a potential upside of 120.33%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Collegium Pharmaceutical is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Collegium Pharmaceutical	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

Supernus Pharmaceuticals has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Collegium Pharmaceutical has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

Collegium Pharmaceutical has a net margin of 5.93% compared to Supernus Pharmaceuticals' net margin of -13.23%. Collegium Pharmaceutical's return on equity of 91.43% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Collegium Pharmaceutical	5.93%	91.43%	15.57%

Collegium Pharmaceutical has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.41	-$38.55M	-$1.92	N/A
Collegium Pharmaceutical	$780.57M	0.92	$62.87M	$1.24	17.83

In the previous week, Collegium Pharmaceutical had 2 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 6 mentions for Collegium Pharmaceutical and 4 mentions for Supernus Pharmaceuticals. Collegium Pharmaceutical's average media sentiment score of 0.03 beat Supernus Pharmaceuticals' score of -0.46 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Collegium Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Collegium Pharmaceutical beats Supernus Pharmaceuticals on 13 of the 14 factors compared between the two stocks.

Get Collegium Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COLL vs. The Competition

Export

Metric	Collegium Pharmaceutical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$719.16M	$12.35B	$7.20B	$13.28B
Dividend Yield	N/A	2.65%	2.53%	16.36%
P/E Ratio	17.81	797.69	274.76	26.18
Price / Sales	0.89	832.00	632.15	98.25
Price / Cash	1.44	86.17	76.82	53.72
Price / Book	2.32	10.71	11.21	6.34
Net Income	$62.87M	$2.84B	$3.50B	$381.90M
7 Day Performance	0.32%	-0.99%	-0.84%	-1.39%
1 Month Performance	-5.44%	-5.86%	-5.42%	-4.31%
1 Year Performance	-33.48%	-5.32%	4.38%	-0.35%

Collegium Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COLL Collegium Pharmaceutical	3.9585 of 5 stars	$22.09 -0.1%	$48.71 +120.5%	-33.3%	$719.80M	$780.57M	3.17	423	Analyst Downgrade
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
MBX MBX Biosciences	3.0188 of 5 stars	$58.54 +0.1%	$83.89 +43.3%	+235.8%	$2.82B	N/A	N/A	63	Positive News
LQDA Liquidia	4.4283 of 5 stars	$27.64 -3.5%	$83.69 +202.8%	+16.4%	$2.56B	$450.91M	20.18	216	Analyst Forecast Insider Trade Analyst Revision Gap Down High Trading Volume
HCM HUTCHMED	0.9949 of 5 stars	$14.31 +0.8%	$14.87 +3.9%	-16.6%	$2.48B	$549.12M	N/A	1,796

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COLL) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Collegium Pharmaceutical (COLL) Competitors

COLL vs. MOR, MBX, LQDA, HCM, and SUPN

How does Collegium Pharmaceutical compare to MorphoSys?

Summary

How does Collegium Pharmaceutical compare to MBX Biosciences?

Summary

How does Collegium Pharmaceutical compare to Liquidia?

Summary

How does Collegium Pharmaceutical compare to HUTCHMED?

Summary

How does Collegium Pharmaceutical compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COLL vs. The Competition

Collegium Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Collegium Pharmaceutical (COLL) Competitors

COLL vs. MOR, MBX, LQDA, HCM, and SUPN

How does Collegium Pharmaceutical compare to MorphoSys?

Which has more risk and volatility, COLL or MOR?

Which has preferable earnings & valuation, COLL or MOR?

Does the media prefer COLL or MOR?

Do institutionals and insiders have more ownership in COLL or MOR?

Is COLL or MOR more profitable?

Do analysts rate COLL or MOR?

Summary

How does Collegium Pharmaceutical compare to MBX Biosciences?

Is MBX or COLL more profitable?

Do analysts rate MBX or COLL?

Which has better valuation and earnings, MBX or COLL?

Does the media refer more to MBX or COLL?

Which has more volatility & risk, MBX or COLL?

Summary

How does Collegium Pharmaceutical compare to Liquidia?

Is LQDA or COLL more profitable?

Which has more risk & volatility, LQDA or COLL?

Does the media refer more to LQDA or COLL?

Which has stronger valuation & earnings, LQDA or COLL?

Do analysts prefer LQDA or COLL?

Do insiders and institutionals have more ownership in LQDA or COLL?

Summary

How does Collegium Pharmaceutical compare to HUTCHMED?

Do insiders & institutionals believe in COLL or HCM?

Which has higher earnings & valuation, COLL or HCM?

Does the media prefer COLL or HCM?

Which has more risk & volatility, COLL or HCM?

Do analysts rate COLL or HCM?

Is COLL or HCM more profitable?

Summary

How does Collegium Pharmaceutical compare to Supernus Pharmaceuticals?

Do analysts recommend SUPN or COLL?

Which has more risk and volatility, SUPN or COLL?

Is SUPN or COLL more profitable?

Which has higher valuation and earnings, SUPN or COLL?

Does the media refer more to SUPN or COLL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COLL vs. The Competition

Collegium Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools